Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

IBERDOMIDE vs IBUPROFEN LYSINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

IBERDOMIDE vs IBUPROFEN LYSINE: Safety Overview

Metric IBERDOMIDE IBUPROFEN LYSINE
Total FAERS Reports 107 277
Deaths Reported 5 27
Death Rate 4.7% 9.7%
Hospitalizations 72 110
Average Patient Age 63.7 yrs 12.6 yrs
% Female Patients 45.0% 46.1%
FDA Approval Date N/A Apr 13, 2006
Manufacturer N/A Recordati Rare Diseases Inc.
Route N/A INTRAVENOUS
Marketing Status N/A Prescription